Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-01 + Nivolumab in Advanced Solid Tumors
NCT05228119Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RT-01 in solid tumor, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Incidence of adverse events up to 6 months, Objective response rate up to 2 years and 6 more. Status: unknown.
02
Drugs
RT-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05228119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228119.